HER2CLIMB was a pivotal randomised phase II study, in which 612 patients with HER2-positive ABC, with or without CNS metastases, were assigned 2:1 to capecitabine and trastuzumab with the addition of tucatinib or placebo [60]. The gene discussed is ERBB2; the disease is aneurysmal bone cyst.